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ance with paliperidone palmitate that is related to less relapses, a better quality of 
life and reduced hospitalization costs.
Mental HealtH – Patient-Reported Outcomes & Patient Preference Studies
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Objectives: To describe the needs of patients treated at community psychosocial 
centers in Sao Paulo, Brazil. MethOds: Cross-sectional study with 373 patients who 
were attending psychosocial care activities at least three times per week in community 
psychosocial centers, during 2007-2008. Needs were assessed using the “Camberwell 
Assessment of Need” (CAN). Psychotic symptoms were assessed using the “Positive 
and Negative Symptom Schedule” (PANSS). Results: Mean age of patients was 40.0 
years (standard deviation, SD = 12.6 years); 57.6% were male, 57.9% had fundamental 
education, 40.5% have schizophrenia, 15.9% have worked during last 12 months and 
14.7% were living alone. Median time attending in community psychosocial centers 
was two years (range of 15 days to 30 years) and mean number of weekly therapeutic 
activities was 3.6 (SD = 2.3). The mean score for the total number of needs was 7.1 
(SD = 2.8), with a range of 0 to 15 (maximum = 22). Basic needs were reported by 38 
(10.2%) patients; at least one social need was reported by 90.9%. At least one function-
ing need was reported by 94.4% patients; 85.5% have at least one health need; 86.3% 
have at least one service need. Women showed higher number of needs than men (p 
= 0.02) and educational until fundamental level was also associated with more needs 
(p = 0.02). We did not observe associations between weekly activities, unemployment, 
age, diagnosis and number of needs. Patients with higher PANSS scores showed more 
needs (p < 0.001). cOnclusiOns: We observed higher number of needs than in stud-
ies conducted in Europe, in all conceptual domains assessed by CAN. Many patients 
showed needs related to health and services, despite the time that they were attending 
in community psychosocial centers. Patients’ needs should take in account in order 
to improve the quality of care offered in mental health services.
Mental HealtH – Health Care use & Policy Studies
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Objectives: To develop the clinical practice guideline major depressive disorder 
for general practitioners in primary and secondary health care setting included 
the diagnosis, differential diagnosis, severity classification and medical treat-
ments. MethOds: A list of 13 key elements of a CPG development process were 
developed that consisted of 1) setting the review teams; 2) determining the problems; 
3) determining health outcomes;4) evidence based literature review; 5) meeting to 
draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by experts; 
8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for CPG train-
ing; 11) preparing for CPG training; 12) evaluating; and 13) improving the CPG related 
with evaluated results. Results: There were 3 main processes in clinical practice 
guideline major depressive disorder for general practitioners in primary and second-
ary health care setting (CPG-MDD-GP) which were 1) Assessment of major depres-
sive disorder (clinical assessment using 9Q screening tool and DSM-TR diagnostic 
criteria, differential diagnosis, diagnosis for major depressive disorder and coding 
of diagnosis); 2) Management of major depressive disorder; and 3) Management of 
hospitalized patients. General practitioners were satisfied with the CPG-MDD-GP in 
trial phase. A total of 416 general practitioners in all provinces were trained to use 
the CPG-MDD-GP then they would be followed and evaluated. Psychiatrists in psy-
chiatric hospitals/ institutes would be available for consultation from the general 
practitioners. cOnclusiOns: The CPG-MDD-GP should be distributed to all general 
practitioners in primary and secondary health care setting. Next step, it would be 
useful for developing the CPG for MDD in the tertiary health care setting.
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Objectives: To identify and describe published articles dealing with issues of men-
tal health in pregnancy from Latin American counties MethOds: Medline, Embase 
and LILACS databases were searched for published studies originating from Latin 
America regarding mental health issues in pregnancy. Search terms included the 
names of all countries in the United States Census Bureau International Database + 
mental health + pregnancy. We included all research and review articles dealing with 
pregnancy and/or lactation, epidemiology of mental disorders, prevention or treat-
ment of mental disorders, outcomes assessment, and counseling/drug information 
dissemination. Excluded were papers dealing exlusively with postpartum depres-
sion, HIV transmission, induction of abortion, in vitro fertilization, contraception or 
the use of alcohol or drugs of abuse. Data were analyzed descriptively. Results: The 
search identified 701 studies; 110 (16%) met the criteria. The earliest was published 
in 1984 and the contribution has increased exponentially [Y= -1E-125*exp(0.1452X), 
where X is the year; R-squared= 0.97). The majority (n= 80; 73%) consisted of original 
research and the other 27% were reviews (23 overviews, 3 systematic reviews/meta-
analyses, 4 other). Most frequent topics were depression (37%) as well as mixed 
anxiety/depression (6%), mental health during pregnancy (32%;), psychotropic drug 
use in pregnancy (13%), suicidality (6%), and quality of life (1%). By country, 58 (53%) 
were produced by Brazil, followed by Mexico (n= 18, 17%), Chile (n= 10, 9%), Colombia 
ics costs were 167.4 times higher than typical antipsychotic costs. AP mean monthly 
costs per person varied with the type of association between antipsychotics: typical-
atypical associations costs were U$257.5± U$228.5, while mean costs between two 
typical antipsychotics were U$4.36 ± U$4.02. Polypharmacy added U$300.00 dolars per 
person per month to direct costs of health care (excluding accomodation). For each 
additional antipsychotic associated, it was observed an additional montlhy costs per 
person of U$87.5 in the total costs of health care package (health services, treatment 
and accomodation). cOnclusiOns: AP added substantial costs and risks to treat-
ment and to health care costs and quality. This should be taken in account in resource 
allocation in public policies, especially in low-resources settings.
PMH7
MOdelizaCión eCOnóMiCa del GenOtiPadO del CitOCROMO P450 COn el 
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ObjectivOs: BrainChip es un test genético que predice la respuesta al tratamiento 
farmacológico de la depresión mayor (DM) determinando los polimorfismos de las 
isoenzimas CYP450. El objetivo ha sido valorar la eficienciade la incorporación del 
test BrainChip previa a la prescripción farmacológica en DM tras fallo en primera 
línea. MetOdOlOgíAs: Se desarrolló un modelo de Markov de ciclos bimensuales para 
cada fármacode una cohorte hipotética depacientes adultos con DM tras fallo en prim-
era línea. La cohorte se adecuó a la distribución del mercado actual y a su modificación 
tras incorporar BrainChip. Los datos de eficacia (no respuesta, respuesta y remisión) 
provienen de revisiones de la literatura y el uso de recursos y costes fue adaptado para 
el análisis inicial a España. Se analizaron los resultados en un horizonte temporal de 1, 3, 
5, 7 y 10 años desde la perspectiva del sistema sanitario aplicando un descuento del 3% 
sobre los efectos y los costes (euros 2011). ResultAdOs: BrainChip mejora la remisión 
entre un 9,5%-11,7% y la respuesta entre 5,5%-10,2%, alcanzando a los 10 años una 
respuesta del 72%. Los pacientes con DM mejoran la calidad de vida con BrainChip entre 
0,04 y 0,25 años de vida ajustados por calidad. El coste de Brainchip se compensa a los 
2 años resultando siempre coste-efectivo a corto plazo y dominante a partir del tercer 
año, mostrando ahorros de 1399€ /paciente tras 10 años. cOnclusiOnes: BrainChip 
en DM es dominante, permite prescribir los tratamientos con menos riesgos y costes y 
más eficacia. El modelo desarrollado permitiría la adaptación del análisis a cualquier 
país de Latinoamérica utilizando datos de costos locales.
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Objectives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide clinical benefit to 
patients. For patients with schizophrenia, non-adherence to medication is a risk factor 
for relapse and re-hospitalization. Long-acting Injectable (LAI) formulations of atypical 
antipsychotics provide constant medication delivery and the potential for improved 
adherence. The objective of this study is to assess the cost-effectiveness of paliperidone 
palmitate (PP) versus risperidone long acting injectable (RLAI), olanzapine (OP) and que-
tiapine (QP). MethOds: A Markov decision analytic model was developed to simulate 
multi-episode patients transitioning through different states on monthly basis over a 
5 year time horizon from the perspective of the Colombian Health System. Probability 
of relapse, level of adherence, side effects, utilities and treatment discontinuation were 
derived from scientific literature. Only direct costs were considered as medications, 
laboratory tests, relapses and adverse events by using national tariffs and prices from 
Ministry of Health medication database. Outcomes were measured as relapses rate and 
Quality Adjusted Life Years (QALY). Discount rate 3%, exchange rate (1 USD = 1,794 COP) 
and threshold considered 3xPIB per capita (USD 20,066 / QALY). Results: Total costs 
(USD): PP (13,338), RLAI (12,635), OP (11,481) and QP (13,247). Hospitalization relapses costs 
(USD): PP (3,276), RLAI (3,341), OP (4,881) and QP (6,840). QALY: PP (3.09), RLAI (3.00), OP 
(2.93) and QP (2.87). Relapses rate: PP (1.35), RLAI (1.38), OP (2.01) and QP (2.81). Incremental 
Cost Utility Ratios (ICUR: USD / QALY): PP vs. RLAI (4,517), PP vs. OP (6,713) and PP vs. QP 
(230). cOnclusiOns: Considering a willingness to pay of USD 20,066 per QALY, the 
incremental cost of PP versus other alternatives could be compensated by its incremen-
tal benefits in terms of relapses avoided and QALY gained. From Health Care Provider 
perspective, PP demonstrates savings in terms of less hospital setting relapsing costs.
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Objectives: To compare from the Guatemaltecan third payer perspective the cost-
effectiveness of paliperidone palmitate with oral quetiapine. MethOds: A Markov 
model was developed to assess the cost-effectiveness and the cost-utility of treat-
ments available for schizophrenia in Guatemala. The model was adjusted to reflect 
the compliance of the patient and the real world effectiveness of both treatments. A 
10 year time horizon was used. All direct medical costs relevant for the third payer 
were included. Four types of side effects were considered in the model: extrapy-
ramidal symptoms, weight gain, diabetes and tardive dyskinesia. Deterministic and 
probabilistic sensitivity analyses were performed. Results: Effectiveness outcomes 
were reported both in QALYs and relapses avoided. The costs were reported in the 
local currency Quetzales and all cost and outcomes were discounted at 5% per year. 
Paliperidone palmitate dominated oral quetiapine by being less expensive (14% less) 
and more effective (44% less relapses and 20% more QALYs). The sensitive analyses 
confirmed the robustness of the results. cOnclusiOns: Paliperidone palmitate 
appeared to be a cost-saving treatment option in comparison with oral quetiapine 
for patients with schizophrenia in Guatemala. The model reflected a better compli-
